GOSS · Gossamer Bio, Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-23 |
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses – SAN DIEGO --(BUSINESS WIRE)--Sep. 23, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and |
| 2026-09-16 |
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Sep. 16, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with |
| 2026-09-11 |
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
SAN DIEGO --(BUSINESS WIRE)--Sep. 11, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension |
| 2026-09-09 |
Gossamer Bio Announces 1-for-80 Reverse Stock Split
SAN DIEGO --(BUSINESS WIRE)--Sep. 9, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension |
| 2026-09-04 |
Gossamer Bio to Present at Cantor Global Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with |
| 2026-08-21 |
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH – – Potential for Up to an Additional $100 Million Upon FDA Approval of Seralutinib – – Financing Includes Participation |
| 2026-08-13 |
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
- NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes - - Gossamer Reacquired Worldwide Development and Commercial Rights to Seralutinib from Chiesi, Consolidating Global Control and Economics - - Stockholders Approved Proposals |
| 2026-07-27 |
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH – – Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity – – Stockholders Approved Proposals Related to |
| 2026-07-01 |
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
SAN DIEGO --(BUSINESS WIRE)--Jul. 1, 2026-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated |
| 2026-06-17 |
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
SAN DIEGO --(BUSINESS WIRE)--Jun. 17, 2026-- Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-09 | Cantor Global Healthcare Conference | Conference |
| 2026-07-27 | Gossamer Bio Business Update | Event |
| 2026-07-27 | Earnings conference call (announced in 8-K) | Earnings call |
| 2026-05-18 | Gossamer Bio Q1 2026 Earnings Call | Earnings call |
| 2026-05-18 | Earnings conference call (announced in 8-K) | Earnings call |
| 2026-02-23 | Gossamer Bio PROSERA Phase 3 Topline Results | Event |
Source: https://ir.gossamerbio.com/